Trial Profile
A Phase IV, Multicentre Randomized Prospective Open Label Study to Evaluate Whether Switching From Current cART to Triumeq in Addition to Adherence Support Will Enhance Virologic Control and Adherence in Vulnerable Populations Relative to Adherence Support Alone
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 01 Sep 2020 Status changed from recruiting to completed.
- 20 Sep 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 20 Sep 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.